ADAPT - A Patient Registry of the Real-world Use of Orenitram®
NCT ID: NCT03045029
Last Updated: 2025-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
300 participants
OBSERVATIONAL
2017-07-18
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
NCT03497689
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
NCT00741819
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
NCT02999906
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
NCT03950739
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
NCT06350032
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral treprostinil
Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
Oral treprostinil
Sustained-release oral tablets for TID administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral treprostinil
Sustained-release oral tablets for TID administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The patient voluntarily gives informed consent to participate in the study.
2. The patient must be at least 18 years of age or older.
3. The patient is prescribed Orenitram (per the package insert indication), and plans to initiate therapy with this medication or has been receiving Orenitram for 182 or fewer days.
4. The patient agrees to dosing, prostacyclin-related AE of interest record keeping, survey participation during designated time periods, and recording any medication changes, use, for the duration of the study.
5. The patient has the ability to answer surveys and use the diary in English.
6. The patient must have an email address and be willing to access the PRO Portal.
Exclusion Criteria
1. The patient has previously received Orenitram for more than 182 days.
2. The patient is currently participating in an investigational drug or device study or has participated in a clinical study with an investigational product other than Orenitram in PAH within
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California - San Francisco
Fresno, California, United States
University of Southern California - Keck Medical Center
Los Angeles, California, United States
Paloma Medical Group
San Juan Capistrano, California, United States
Santa Barbara Pulmonary Associates
Santa Barbara, California, United States
Harbor UCLA Medical Center
Torrance, California, United States
Aurora Denver Cardiology Associates
Aurora, Colorado, United States
Pueblo Pulmonary Associates
Pueblo, Colorado, United States
Lung Associates PA
Bradenton, Florida, United States
University of Florida Clinical Research Center
Gainesville, Florida, United States
St. Vincent's Lung, Sleep, and Critical Care Specialists
Jacksonville, Florida, United States
AdventHealth Orlando
Orlando, Florida, United States
Central Florida Pulmonary Group, P.A.
Orlando, Florida, United States
USF South Florida Heart Health
Tampa, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
Piedmont Healthcare/Research
Austell, Georgia, United States
Loyola University Chicago
Chicago, Illinois, United States
Saint Vincent Hospital and Health Services
Indianapolis, Indiana, United States
University Of Iowa Hospital and Clinics
Iowa City, Iowa, United States
University of Louisville Physicians Outpatient Center
Louisville, Kentucky, United States
Chest Medicine Associates
South Portland, Maine, United States
Mclaren Greater Lansing
Okemos, Michigan, United States
Beaumont Hospital Troy
Troy, Michigan, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Albany Medical College
Albany, New York, United States
New York Methodist Hospital
Brooklyn, New York, United States
Pulmonary Health Physicians, PC
Fayetteville, New York, United States
Stony Brook University Medical Center
Islandia, New York, United States
Northwell Health- Long Island Jewish Forest Hills
New Hyde Park, New York, United States
University of Rochester
Rochester, New York, United States
Pinehurst Medical Clinic, INC.
Pinehurst, North Carolina, United States
Lima Memorial Hospital
Lima, Ohio, United States
INTEGRIS Nazih Zuhdi Transplant Institution
Oklahoma City, Oklahoma, United States
Oregon Health & Science University (OHSU)
Portland, Oregon, United States
University of Pittsburgh - Heart and Vascular Medicine Institute
Pittsburgh, Pennsylvania, United States
AnMed Health Pulmonary and Sleep Medicine
Anderson, South Carolina, United States
Center for Biomedical Research
Knoxville, Tennessee, United States
Baylor University Medical Center
Dallas, Texas, United States
Houston Methodist Research Institute
Houston, Texas, United States
Renovatio Clinical
The Woodlands, Texas, United States
Carilion Clinic
Roanoke, Virginia, United States
Heart Care Associates, LLC
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TDE-PH-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.